Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 11%, in line with ...

Novo launched a rival bid to acquire American obesity biotech firm Metsera last week, superseding an offer for the firm from ...

COPENHAGEN () -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in a ...

The lowest doses of Eli Lilly’s Zepbound and Novo Nordisk's Wegovy could be available for as little as $149 a month.

Pfizer CEO Albert Bourla called Novo Nordisk's bid for obesity drug developer Metsera an "illegal...end-run around antitrust laws." ...

The White House is close to announcing a deal with drugmakers Eli Lilly and Novo Nordisk that would cut the price of obesity drugs to $149 per month in some cases and extend coverage to certain ...

A novel machine learning gene risk biomarker test successfully predicted patient response to semaglutide treatment after ...